MISC

査読有り 国際誌
2019年3月

A Phase II study of the safety and efficacy of lenvatinib in patients with advanced thyroid cancer.

Future oncology (London, England)
  • Shunji Takahashi
  • ,
  • Naomi Kiyota
  • ,
  • Tomoko Yamazaki
  • ,
  • Naoko Chayahara
  • ,
  • Kenji Nakano
  • ,
  • Lina Inagaki
  • ,
  • Kazuhisa Toda
  • ,
  • Tomohiro Enokida
  • ,
  • Hironobu Minami
  • ,
  • Yoshinori Imamura
  • ,
  • Naoki Fukuda
  • ,
  • Tatsuya Sasaki
  • ,
  • Takuya Suzuki
  • ,
  • Hiroki Ikezawa
  • ,
  • Corina E Dutcus
  • ,
  • Makoto Tahara

15
7
開始ページ
717
終了ページ
726
記述言語
英語
掲載種別
DOI
10.2217/fon-2018-0557

AIM: To investigate the safety and efficacy of lenvatinib in advanced thyroid cancer. PATIENTS/METHODS: In this Phase II study, 51 Japanese patients with radioiodine-refractory differentiated thyroid cancer (RR-DTC), medullary thyroid cancer (MTC) or anaplastic thyroid cancer (ATC) received once-daily lenvatinib 24 mg. The primary end point was safety. RESULTS: All patients experienced ≥1 adverse event (AE); only one patient experienced an AE leading to discontinuation. The most common any-grade AEs were hypertension, decreased appetite, palmar-plantar erythrodysesthesia, fatigue and proteinuria. Response rates for RR-DTC: 68%; MTC: 22%; ATC: 24%. Median progression-free survival for RR-DTC: 25.8 months; MTC: 9.2 months; ATC: 7.4 months. CONCLUSION: Lenvatinib demonstrated a manageable safety profile, proven antitumor activity in RR-DTC and promising efficacy in MTC and ATC. CLINICAL TRIAL REGISTRATION: clinicaltrials.gov NCT01728623.

リンク情報
DOI
https://doi.org/10.2217/fon-2018-0557
PubMed
https://www.ncbi.nlm.nih.gov/pubmed/30638399

エクスポート
BibTeX RIS